Aurobindo Pharma · NSE: AUROPHARMA · BSE: 524804

Q4 FY20 results · Jan–Mar 2020

Aurobindo Pharma reported revenue from operations of ₹6,158.43 crore (up 16.4% from Q4 FY19) and net profit of ₹848.99 crore (up 45.1% from Q4 FY19) for Q4 FY20 (Jan–Mar 2020), on a consolidated basis.

Consolidated · ₹ crore
Item	Q4 FY20	Q4 FY19	YoY	Q3 FY20	QoQ
Revenue from operations	6,158.43	5,292.20	+16.4%	5,895.00	+4.5%
Other income	32.59	32.27	+1.0%	21.99	+48.2%
Total income	6,191.02	5,324.47	+16.3%	5,916.99	+4.6%
Profit before share of associates & JVs and tax	1,096.82	816.86	+34.3%	938.81	+16.8%
Share of profit/(loss) of associates & JVs	(19.31)	(0.52)		(0.64)
Net profit for the period	848.99	585.22	+45.1%	705.31	+20.4%
Attributable to shareholders of the company	849.83	585.38	+45.2%	705.45	+20.5%
EPS, basic (₹)	14.50	9.99	+45.1%	12.04	+20.4%
Net margin (%)	13.8	11.1		12.0

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q4 FY20	Q4 FY19	YoY	Q3 FY20	QoQ
Revenue from operations	3,620.32	3,280.58	+10.4%	3,345.67	+8.2%
Other income	160.61	28.31	+467.3%	16.88	+851.5%
Total income	3,780.93	3,308.89	+14.3%	3,362.55	+12.4%
Profit before tax	872.89	618.48	+41.1%	549.30	+58.9%
Net profit for the period	725.04	460.14	+57.6%	419.07	+73.0%
EPS, basic (₹)	12.37	7.85	+57.6%	7.15	+73.0%
Net margin (%)	20.0	14.0		12.5

Consolidated

Filed with BSE: 04 Jun 2020, 13:23 IST
Board meeting: 03 Jun 2020
Period: 01 Jan 2020 to 31 Mar 2020
Review status: Audited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 04 Jun 2020, 13:23 IST
Board meeting: 03 Jun 2020
Period: 01 Jan 2020 to 31 Mar 2020
Review status: Audited
Source: XBRL filing on BSE